ADVERSE DRUG REACTIONS AND DRUG INTERACTIONS OF TAXANES

Paclitaxel and docetaxel are key chemotherapy agents for various cancers, but their use is often limited by adverse drug reactions (ADRs) and drug–drug interactions. A review of clinical and pharmacokinetic studies was performed to identify major ADRs and interaction mechanisms. Adverse drug reactions of taxanes frequently include neutropenia, peripheral neuropathy (worsened by cumulative dosing), hypersensitivity (linked to solvents Cremophor EL and polysorbate 80), alopecia, mucositis, and GI upset. Both drugs are metabolised by CYP3A4 and CYP2C8. CYP inhibitors can raise toxicity risk; inducers may reduce efficacy. The timing of taxanes with agents like cisplatin or anthracyclines also impacts toxicity and effectiveness. Effective use of taxanes requires vigilant monitoring, personalised dosing, premedication, and awareness of interactions. These strategies help maximise efficacy and minimise harm.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-07-04
DOI
https://doi.org/10.5281/zenodo.15806676
Primary Topic
Radiation Dose and Imaging
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ADVERSE DRUG REACTIONS AND DRUG INTERACTIONS OF TAXANES

Zenodo (CERN European Organization for Nuclear Research)
Radiation Dose and Imaging
article

ADVERSE DRUG REACTIONS AND DRUG INTERACTIONS OF TAXANES

article en

Abstract

Paclitaxel and docetaxel are key chemotherapy agents for various cancers, but their use is often limited by adverse drug reactions (ADRs) and drug–drug interactions. A review of clinical and pharmacokinetic studies was performed to identify major ADRs and interaction mechanisms. Adverse drug reactions of taxanes frequently include neutropenia, peripheral neuropathy (worsened by cumulative dosing), hypersensitivity (linked to solvents Cremophor EL and polysorbate 80), alopecia, mucositis, and GI upset. Both drugs are metabolised by CYP3A4 and CYP2C8. CYP inhibitors can raise toxicity risk; inducers may reduce efficacy. The timing of taxanes with agents like cisplatin or anthracyclines also impacts toxicity and effectiveness. Effective use of taxanes requires vigilant monitoring, personalised dosing, premedication, and awareness of interactions. These strategies help maximise efficacy and minimise harm.

Zenodo (CERN European Organization for Nuclear Research)
Kerala University of Health Sciences (IN)
Good health and well-being
Openalex Percentile: Top 40%
Radiation Dose and Imaging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.